Dostarlimab is under clinical development by GSK and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction.

Tevimbra is already approved in the US for the treatment of unresectable or metastatic oesophageal squamous cell carcinoma ...

Lenvatinib mesylate is under clinical development by Eisai and currently in Phase III for Gastric Cancer. According to GlobalData, Phase III drugs for Gastric Cancer have a 46% phase transition ...

More research is needed to refine treatment strategies and identify predictive biomarkers for patient selection, according to researchers.

San Mateo, California Monday, December 30, 2024, 18:00 Hrs [IST] ...

The Food and Drug Administration (FDA) has approved Tevimbra (tislelizumab-jsgr) in combination with platinum and ...

BeiGene (BGNE) has received U.S. FDA approval for its cancer drug Tevimbra in combination with chemotherapy for certain ...

The FDA has approved tislelizumab plus chemotherapy for the treatment of patients with newly diagnosed, locally advanced or ...

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today annou ...